Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | HK2 | P52789 | 3/20 | 0.33 |
| ▸ | HK1 | P19367 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16728933 | 1.00 | MAPK1 (0.40) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL29535657 | 0.90 | LGALS3 (0.36) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL29535345 | 0.88 | LGALS3 (0.38) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL29534894 | 0.86 | F10 (0.43) | LGALS3CA2F10 | |
| SCHEMBL16729068 | 0.86 | LGALS3 (0.36) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL7121030 | 0.83 | LGALS8 (0.47) | LGALS3CA12CA1CA2CA9 | |
| SCHEMBL7121026 | 0.83 | LGALS8 (0.47) | LGALS3CA12CA1CA2CA9 | |
| SCHEMBL741519 | 0.82 | SLC2A1 (0.42) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL5318200 | 0.82 | SLC2A1 (0.42) | MAPK1LGALS3CA12CA1CA2 | |
| SCHEMBL150778 | 0.82 | SLC2A1 (0.42) | MAPK1LGALS3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116622006-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2025-05-30 | — | — | CN | claimed |
| CN-110446511-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2024-04-02 | — | — | CN | claimed |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-29 | — | — | US | claimed |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | claimed |
| CN-116622006-A | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2023-08-22 | — | — | CN | claimed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | claimed |
| WO-2026041790-A1 | DI(DISPIRODIAZATRIPIPERAZINE)-TRIAZINE DERIVATIVES AND THEIR USE FOR TREATMENT OR PREVENTION OF VIRAL INFECTIONS | Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts (DE) | 2026-02-26 | — | — | WO | disclosed |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-02-03 | — | — | US | disclosed |
| CN-116622006-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2025-05-30 | — | — | CN | disclosed |
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4426750-A2 | METHODS FOR THE CHEMOENZYMATIC SYNTHESIS OF LOW MOLECULAR WEIGHT HEPARIN FROM LOW MOLECULAR WEIGHT HEPAROSAN | Rensselaer Polytechnic Institute (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-110446511-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2024-04-02 | — | — | CN | disclosed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-114814010-A | Two-dimensional liquid phase-mass spectrum combined method for low molecular weight heparin mass analysis | 苏州大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022124944-A1 | DI(DIAZONIADISPIRO[5.2.5.2]HEXADECAN)-5-NITROPYRIMIDINES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | FEDERAL RESEARCH CENTRE “FUNDAMENTALS OF BIOTECHNOLOGY” OF THE RUSSIAN ACADEMY OF SCIENCES (RU) | 2022-06-16 | — | — | WO | disclosed |
| CN-114591451-A | Partial anticoagulant heparin derivative and preparation method and application thereof | 苏州大学 | 2022-06-07 | — | — | CN | disclosed |
| EP-3011043-B1 | REVERSIBLE HEPARIN MOLECULES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | HPSE, STS, SULT1A1 | MAPK1 2401/4885LGALS3 3457/4885CA12 376/4885 |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | HPSE, STS, SULT1A1 | MAPK1 2401/4885LGALS3 3457/4885CA12 376/4885 |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | STS, TPST2, HPSE | MAPK1 2281/4885LGALS3 2892/4885CA12 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.